| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
November 30, 2004 |
|
|
| |
|
|
| |
|
|
|
Cambridge Healthtech Institute, San Francisco, California
February 7-8, 2005
Over 300 delegates gathered at the Inaugural Biomarker Validation meeting in May 2004. During the 3-day intensive program, it became clear that the term “biomarker validation” in itself is meaningless, unless taken in context of a specific purpose that the biomarker is expected to serve. The Second Annual Biomarker Validation meeting will offer case studies of clinical applications of biomarkers and review validation criteria for each of these applications. Biomarker translation from pre-clinical to clinical phases will also be covered, with special emphasis on strategies to enable better decision making that results in decreased late-stage attrition and shortened development cycles by improving the quality of drug candidates at every stage of the development pipeline. Given the amount of progress being made at pharmaceutical and diagnostic companies in establishing biomarker best practices and adopting biomarker strategies at the pre-clinical/clinical interface and Phase I and II clinical trials, we paired the Biomarker Validation meeting with the Translational Research meeting. The pharmaceutical decision makers are also invited to attend the Executive ThinkTank on Biomarker Strategies in Go/No-Go Decisions.
|
|
|
|
|
|
|
|
Organized by:
|
|
CHI |
|
|
Invited Speakers:
|
|
For more info, visit www.healthtech.com/2005/bmv/index.asp
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
.
|
|
|
|
|
|
|
|
Registration:
|
|
For more info, visit www.healthtech.com/2005/bmv/index.asp
|
|
|
E-mail:
|
|
chi@healthtech.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|